ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO992

Investigating Hepatocyte Nuclear Factor 4 Alpha as a Central Regulator of Kidney Graft Repair

Session Information

  • Transplantation: Basic
    October 25, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 2101 Transplantation: Basic

Authors

  • Neupane, Slaghaniya, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Petrovic, Stefan, University Health Network, Toronto, Ontario, Canada
  • Saha, Aninda Dibya, Stanford Medicine, Stanford, California, United States
  • Allen, Maya A., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Sachewsky, Nadia, University Health Network, Toronto, Ontario, Canada
  • John, Rohan, University Health Network, Toronto, Ontario, Canada
  • Selzner, Markus, University Health Network, Toronto, Ontario, Canada
  • Robinson, Lisa, Sick Kids Foundation, Toronto, Ontario, Canada
  • Clotet Freixas, Sergi, McMaster University, Hamilton, Ontario, Canada
  • Konvalinka, Ana, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
Background

Kidney transplantation is the optimal treatment for end-stage kidney disease. However, ischemia-reperfusion injury (IRI) harms all transplanted kidneys, limiting their short- and long-term survival. Previously, we determined that superior kidney function/structure after IRI is associated with preserved expression of mitochondrial proteins during normothermic ex vivo kidney perfusion (NEVKP). We identified a potential transcriptional regulator of these mitochondrial proteins, hepatocyte nuclear factor 4a (HNF4A), which may present a novel target for kidney repair. Our goal is to determine whether a novel HNF4A agonist, N-trans caffeoyltyramine (NCT), protects kidneys from IRI. We will evaluate the effectiveness of NCT treatment in vitro studying male and female primary proximal tubular cells (PTECs), and in vivo studying male and female mice.

Methods

First, we inhibited HNF4A in primary male and female PTECs, using a pharmacologic or genetic approach. We then assessed gene expression, cell death and mitochondrial function. Next, we treated PTECs with NCT/vehicle and examined cell death and expression of HNF4A target genes. Lastly, male and female mice were subjected to bilateral IRI, and kidney function and structure were assessed on post-operative day 2 and 14.

Results

HNF4A inhibition in vitro increased PTEC death and decreased mitochondrial function, while NCT increased the expression of HNF4A and mitochondrial genes, suggesting that NCT may be protective. We developed a sex-specific model of bilateral IRI and demonstrated that warm ischemia (27-minutes in males, 40-minutes in females) impairs kidney function on post-operative day 2, indicated by elevated serum creatinine and tubular injury. Mice also developed tubulointerstitial fibrosis on post-operative day 14.

Conclusion

Based on the preliminary results, HNF4A is important for the metabolic function and viability of PTECs. We will next administer NCT to mice prior to IRI and examine whether HNF4A agonist preserves mitochondria and improves kidney function and structure.